基础医学与临床 ›› 2018, Vol. 38 ›› Issue (7): 1012-1015.

• 短篇综述 • 上一篇    下一篇

嵌合抗原受体基因修饰的T细胞免疫治疗骨肉瘤的研究进展

童晨曦,宋银宏   

  1. 三峡大学医学院
  • 收稿日期:2017-03-27 修回日期:2017-07-14 出版日期:2018-07-05 发布日期:2018-06-29
  • 通讯作者: 宋银宏 E-mail:syh728@126.com
  • 基金资助:
    国家自然科学基金

Progress of chimeric antigen receptor-modified T cell therapy for osteosarcoma

Chen-Xi TONG1,Yin-Hong SONG   

  • Received:2017-03-27 Revised:2017-07-14 Online:2018-07-05 Published:2018-06-29
  • Contact: Yin-Hong SONG E-mail:syh728@126.com

摘要: 骨肉瘤(OS)是一种常见骨恶性肿瘤。常规治疗方式对患者预后生存率有一定改善,但对已转移患者的作用十分有限。靶向骨肉瘤相关抗原的嵌合抗原受体基因修饰的T细胞(CAR-T)疗法是一种很有前景的治疗方式。包括靶向HER-2、IL-11Rα、ROR1和GD2等骨肉瘤相关抗原的特异性CAR-T治疗在一些基础和临床研究中均有报道,且已经表现出了对骨肉瘤良好的治疗效果。

关键词: 关键词:嵌合抗原受体基因修饰的T细胞, 骨肉瘤, 免疫治疗

Abstract: Osteosarcoma(OS) is one common type of bone malignancy. Conventional treatments improved survival dramatically. However, conventional therapies reveal the limited effects for patients with metastatic disease. Targeting osteosarcoma-associated antigen, chimeric antigen receptor-modified T cell(CAR-T) therapy is promising treatment. Specific CAR-T treatments of osteosarcoma including targeting HER-2, IL-11Rα, ROR1 and GD2 have shown a certain therapeutic effect on osteosarcoma in some basic and clinical studies.

Key words: Key words: chimeric antigen receptor-modified T(CAR-T)cell, osteosarcoma, immunotherapy

中图分类号: